GU Cancers 2024 | Molecular and immunologic insights in prostate cancer based on site of metastasis

Umang Swami, MD, MS, University of Utah, Salt Lake City, UT, discusses the molecular and immunologic nuances of metastatic prostate cancer in a real-world dataset. Visceral metastases exhibited higher mutation rates in various genes compared to non-visceral and primary prostate cancer. Visceral and non-visceral metastases also showed elevated androgen receptor signaling, interferon-γ scores, and PD-L1 positivity. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.